Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cougar Biotechnology, Inc.
CORRECTING and REPLACING Cougar Biotechnology’s Board of Directors Recommends Stockholders Accept Johnson & Johnson’s $43.00 Per Share Cash Tender Offer
June 28th, 2009
In first graph, first sentence of release, stock exchange for Johnson & Johnson, should read: NYSE (sted NASDAQ). The corrected release reads: COUGAR BIOTECHNOLOGY'S BOARD OF DIRECTORS RECOMMENDS STOCKHOLDERS ACCEPT JOHNSON & JOHNSON'S $43.00 PER SHARE CASH TENDER OFFER Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced that its board of directors has unanimously agreed to recommend that stockholders tender their shares to Johnson & Johnson (NYSE: JNJ) at the previously announced price of $43.00 per share. The directors also indicated that they intend to tender all their shares of Cougar Biotechnology. The transaction is expected to close during the...
Source: Pharma Investments, Ventures & Law Weekly (2009-06-28)
|
